Sam Kim

Samuel Kim is a highly experienced Principal Scientist and Director at Merck, with a notable background that includes roles at Acceleron Pharma and Gilead Sciences. At Merck, Samuel leads significant clinical trials focused on pulmonary arterial hypertension (PAH) and has a proven track record in regulatory document preparation and scientific management. Prior experience as a Clinical Research Scientist includes contributions to collaborative studies analyzing immune responses and extensive work in protocol development and clinical research at the University of Florida. Samuel holds a PhD in Molecular Cell Biology from the University of Florida and advanced degrees in Molecular Genetics and Life Science from Korea University, demonstrating a strong academic foundation in the life sciences.